In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Esperion Therapeutics Inc.

www.esperion.com

Latest From Esperion Therapeutics Inc.

Finance Watch: Ayala Launches First Biopharma IPO In May

The cancer drug developer raised $55m. Also, Lyra raised $56m in the last of four biopharma IPOs in April, Biogen sold $3bn worth of debt, Oberland raised a $1.05bn fund and Praxis launched with more than $100m. 

Financing Innovation

Deal Watch: Novartis Partners With TScan To Develop T-Cell Receptor-Targeted Therapies

Novartis/TScan and Gilead/Kite/oNKo-innate partnerships seek to advance cancer cell therapy. J&J, Bayer among the latest pharmas to unveil partnerships to fight the novel coronavirus.

Deals Business Strategies

Daiichi Sankyo Enters Europe's Cholesterol Market

The Japan-headquartered drugmaker says there is a need for affordable oral treatment options on top of currently available lipid-lowering therapies and the two drugs it licensed from Esperion can meet that need.

Cardiovascular Approvals

Keeping Track: Two Novel Migraine Drugs Highlight Busy Week For US FDA Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

Approvals US FDA Performance Tracker
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Esperion Therapeutics Inc.
  • Pfizer Inc.
  • Senior Management
  • Timothy Mayleben, Pres. & CEO
    Rick Bartram, CFO
    Narendra Lalwani, PhD, EVP, R&D
    Mark Glickman, Chief Commercial Officer
  • Contact Info
  • Esperion Therapeutics Inc.
    Phone: (734) 862-4840
    3891 Ranchero Dr., Ste. 150
    Ann Arbor, MI 48108
    USA
UsernamePublicRestriction

Register